Grufity logoGrufity logo

Edwards Lifesciences Corp Stock Research

EW

81.91USD+2.43(+3.06%)Delayed

Market Summary

USD81.91+2.43
Delayed
3.06%

EW Alerts

EW Stock Price

EW RSI Chart

EW Valuation

Market Cap

49.8B

Price/Earnings (Trailing)

32.74

Price/Sales (Trailing)

9.26

EV/EBITDA

25.47

Price/Free Cashflow

51.18

EW Price/Sales (Trailing)

EW Profitability

EBT Margin

32.84%

Return on Equity

26.21%

Return on Assets

18.35%

Free Cashflow Yield

1.95%

EW Fundamentals

EW Revenue

Revenue (TTM)

5.4B

Revenue Y/Y

1.4%

Revenue Q/Q

2.22%

EW Earnings

Earnings (TTM)

1.5B

Earnings Y/Y

18.82%

Earnings Q/Q

15.98%

Price Action

52 Week Range

67.13131.10
(Low)(High)

Last 7 days

2.9%

Last 30 days

2.4%

Last 90 days

8.1%

Trailing 12 Months

-25.1%

EW Financial Health

Current Ratio

3.03

EW Investor Care

Buy Backs (1Y)

2.53%

Diluted EPS (TTM)

2.44

Peers (Alternatives to Edwards Lifesciences)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
105.5B
30.8B
-7.09% -24.59%
25.94
3.43
-3.19% -17.38%
104.1B
18.4B
2.26% 8.00%
44.16
5.64
7.84% 18.25%
84.2B
6.2B
-4.47% -13.27%
63.66
13.53
8.97% -22.43%
67.4B
19.0B
-5.16% -6.78%
41.86
3.55
-0.43% -8.78%
49.8B
5.4B
2.41% -25.12%
32.74
9.26
2.86% 1.25%
MID-CAP
7.2T
489.7M
9.34% 31.15%
82.2K
16.8K
106.51% 2464.23%
10.2B
847.1M
-3.64% 34.52%
-5.1K
12.05
13.32% -137.89%
5.2B
1.0B
-11.64% -20.31%
30.19
5.09
6.76% 24.45%
3.5B
410.9M
4.51% -3.13%
-29.82
8.43
27.29% -14.60%
2.7B
801.2M
1.13% -58.87%
-28.25
3.34
14.00% -707.69%
SMALL-CAP
1.7B
138.6M
-15.68% 29.18%
-30.43
12.07
36.62% -10.44%
1.3B
820.0M
-8.35% -12.22%
25.89
1.59
10.13% 701.59%
853.3M
154.8M
-6.04% 0.61%
-8.2
5.51
60.29% -2309.58%
828.4M
239.8M
0.30% 1.49%
-21.88
3.45
-4.74% -31.15%

Financials for Edwards Lifesciences

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue0.3%5,3825,3645,3555,3575,233
Gross Profit1.7%4,3024,2324,1654,1023,984
  S&GA Expenses-0.8%1,5681,5811,5681,5331,494
  R&D Expenses-0.1%945946950925903
EBITDA4.1%1,9261,8501,8241,905-
EBITDA Margin3.8%0.36*0.34*0.34*0.36*-
Earnings Before Taxes4.9%1,7671,6841,6681,7491,702
EBT Margin4.6%0.33*0.31*0.31*0.33*-
Interest Expenses-32.2%19.0028.0021.0019.0018.00
Net Income4.3%1,5221,4591,4551,5391,503
Net Income Margin4.0%0.28*0.27*0.27*0.29*-
Free Cahsflow-6.7%9741,0441,2651,432-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-4.0%8,2938,6388,4258,4208,503
  Current Assets-11.9%3,0963,5143,2633,2413,181
    Cash Equivalents-38.4%7691,2481,1981,031863
  Inventory15.5%876758740731727
  Net PPE4.2%1,6331,5661,5601,5521,547
  Goodwill0.5%1,1641,1591,1641,1661,168
Liabilities2.7%2,4862,4202,4822,5752,667
  Current Liabilities11.4%1,0229189699501,032
    LT Debt, Non Current0.0%596596596596596
Shareholder's Equity-6.6%5,8076,2185,9445,8455,836
  Retained Earnings5.5%7,5907,1926,8486,4426,068
  Additional Paid-In Capital2.9%1,9691,9151,8531,7691,700
Accumulated Depreciation14.6%750655---
Shares Outstanding-1.8%608619620621624
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-6.9%1,2181,3091,5311,7251,732
  Share Based Compensation3.0%127123119114109
Cashflow From Investing131.2%252-808-984-1,443-1,722
Cashflow From Financing-96.1%-1,584-808-699-450-356
  Buy Backs80.4%1,727958859616513

Risks for EW

What is the probability of a big loss on EW?

39.6%


Probability that Edwards Lifesciences stock will be more than 20% underwater in next one year

31.9%


Probability that Edwards Lifesciences stock will be more than 30% underwater in next one year.

8.1%


Probability that Edwards Lifesciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does EW drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Edwards Lifesciences was unfortunately bought at previous high price.

Drawdowns

Returns for EW

Cumulative Returns on EW

33.1%


10-Year Cumulative Returns

35.4%


7-Year Cumulative Returns

38.1%


5-Year Cumulative Returns

56.8%


3-Year Cumulative Returns

What are the long-term rolling returns for EW?

FIve years rolling returns for Edwards Lifesciences.

Annualized Returns

Which funds bought or sold EW recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-12.31
-678,508
2,579,490
0.07%
2023-03-13
Claro Advisors LLC
reduced
-15.7
-206,942
405,058
0.13%
2023-03-10
MATHER GROUP, LLC.
added
122
240,355
477,355
0.01%
2023-03-10
MATHER GROUP, LLC.
sold off
-100
-402,000
-
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-61.4
-33,648,700
18,003,300
0.02%
2023-03-10
BAILLIE GIFFORD & CO
added
0.77
-3,216,020
32,492,000
0.03%
2023-03-08
Capital Asset Advisory Services LLC
new
-
303,887
303,887
0.02%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-80.43
-22,180,000
4,760,000
0.02%
2023-03-03
TIAA, FSB
reduced
-88.56
-7,335,270
844,734
-%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
72,412,600
72,412,600
0.90%

1–10 of 48

Latest Funds Activity

Are funds buying EW calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own EW
No. of Funds

Edwards Lifesciences News

MarketBeat

Beese Fulmer Investment Management Inc. Grows Holdings in ....

MarketBeat,
3 hours ago

Orange County Business Journal

NFL Stars Compete With Local Investors at RX3 Flag Football ....

Orange County Business Journal,
45 hours ago

Nasdaq

Schedule 13G FIlings of Edwards Lifesciences

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
8.34%
51,559,391
SC 13G/A
Feb 07, 2023
blackrock inc.
8.6%
53,060,508
SC 13G/A
Feb 09, 2022
vanguard group inc
7.86%
49,076,649
SC 13G/A
Feb 03, 2022
blackrock inc.
9.1%
57,040,983
SC 13G/A
Feb 10, 2021
vanguard group inc
7.76%
48,347,685
SC 13G/A
Jan 29, 2021
blackrock inc.
9.4%
58,596,560
SC 13G/A
Feb 12, 2020
vanguard group inc
7.79%
16,261,702
SC 13G/A
Feb 05, 2020
blackrock inc.
8.7%
18,200,799
SC 13G/A

EW Fair Value

Edwards Lifesciences fair value in different scenarios

The table shows the Fair Value estimates for Edwards Lifesciences for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

34.98

-57.29%

45.99

-43.85%

62.21

-24.05%

80.13

-2.17%

94.13

14.92%
Current Inflation

32.13

-60.77%

41.56

-49.26%

55.09

-32.74%

69.98

-14.56%

81.59

-0.39%
Very High Inflation

28.63

-65.05%

36.22

-55.78%

46.71

-42.97%

58.26

-28.87%

67.21

-17.95%

Historical Edwards Lifesciences Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Edwards Lifesciences

View All Filings
Date Filed Form Type Document
Mar 15, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
PRE 14A
PRE 14A
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Feb 21, 2023
8-K
Current Report
Feb 21, 2023
4
Insider Trading
Feb 17, 2023
4
Insider Trading
Feb 17, 2023
4
Insider Trading
Feb 16, 2023
4
Insider Trading

Latest Insider Trading transactions for EW

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-15
Chopra Daveen
acquired
200,802
45.2767
4,435
cvp, tmtt
2023-03-15
Chopra Daveen
sold
-343,563
77.4662
-4,435
cvp, tmtt
2023-03-14
MUSSALLEM MICHAEL A
acquired
1,033,900
35.1967
29,375
chairman & ceo
2023-03-14
MUSSALLEM MICHAEL A
gifted
-
-
9,500
chairman & ceo
2023-03-14
MUSSALLEM MICHAEL A
sold
-1,542,510
77.6107
-19,875
chairman & ceo
2023-03-14
MUSSALLEM MICHAEL A
gifted
-
-
-9,500
chairman & ceo
2023-03-08
Lemercier Jean-Luc M
acquired
233,706
35.1967
6,640
cvp, emeacla and japac
2023-03-08
Lemercier Jean-Luc M
sold
-510,996
76.9573
-6,640
cvp, emeacla and japac
2023-03-08
BOBO DONALD E JR
sold
-517,558
76.9603
-6,725
cvp,strategy/corp development
2023-03-08
BOBO DONALD E JR
acquired
236,698
35.1967
6,725
cvp,strategy/corp development

1–10 of 50

Michael A. Mussallem
15700
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

EW Income Statement

2022-09-30
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Net sales$ 1,319.0$ 1,310.2$ 4,034.1$ 3,902.8
Cost of sales253.8311.7822.5939.4
Gross profit1,065.2998.53,211.62,963.4
Selling, general, and administrative expenses377.3364.41,156.61,069.7
Research and development expenses233.6238.0713.0670.3
Intellectual property litigation (income) expenses, net(2.4)4.710.813.5
Change in fair value of contingent consideration liabilities, net (Note 7)(12.5)1.1(36.3)(106.0)
Special charge (Note 3)66.80.066.80.0
Operating income402.4390.31,300.71,315.9
Interest (income) expense, net(6.9)0.8(8.4)1.5
Other expense (income), net2.0(1.4)1.0(11.3)
Income before provision for income taxes407.3390.91,308.11,325.7
Provision for income taxes63.850.8184.6157.9
Net income$ 343.5$ 340.1$ 1,123.5$ 1,167.8
Earnings per share:    
Basic (in dollars per share)$ 0.55$ 0.55$ 1.81$ 1.87
Diluted (in dollars per share)$ 0.55$ 0.54$ 1.79$ 1.85
Weighted-average number of common shares outstanding:    
Basic (in shares)619.8623.6621.0623.0
Diluted (in shares)624.5631.7626.9631.0

EW Balance Sheet

2022-09-30
CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 1,247.8$ 862.8
Short-term investments (Note 4)490.9604.0
Accounts receivable, net of allowances of $7.5 and $9.3, respectively618.1582.2
Other receivables43.382.7
Inventories (Note 2)757.8726.7
Prepaid expenses88.485.2
Other current assets267.6237.1
Total current assets3,513.93,180.7
Long-term investments (Note 4)1,381.01,834.2
Property, plant, and equipment, net1,566.41,546.6
Operating lease right-of-use assets87.792.1
Goodwill1,158.71,167.9
Other intangible assets, net (Note 3)266.5323.6
Deferred income taxes347.5246.7
Other assets (Note 5)316.5110.8
Total assets8,638.28,502.6
Current liabilities  
Accounts payable154.9204.5
Accrued and other liabilities (Note 2)739.5802.3
Operating lease liabilities23.525.5
Total current liabilities917.91,032.3
Long-term debt596.2595.7
Contingent consideration liabilities (Note 7)25.762.0
Taxes payable142.9190.0
Operating lease liabilities67.169.1
Uncertain tax positions295.6259.0
Litigation settlement accrual (Note 2)153.9191.3
Other liabilities221.1267.3
Total liabilities2,420.42,666.7
Commitments and contingencies (Note 11)
Stockholders' equity  
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding          0.00.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 645.7 and 642.0 shares issued, and 619.4 and 624.1 shares outstanding, respectively645.7642.0
Additional paid-in capital1,914.51,700.4
Retained earnings7,191.66,068.1
Accumulated other comprehensive loss (Note 12)(256.0)(157.7)
Treasury stock, at cost, 26.3 and 17.9 shares, respectively(3,278.0)(2,416.9)
Total stockholders' equity6,217.85,835.9
Total liabilities and stockholders' equity$ 8,638.2$ 8,502.6